Tsutomu Odakura

Electrocardiographic and hematological changes by exercise test in coronary patients and pyridinolcarbamate pretreatment. A double-blind crossover trial.

Abstract Forty hospitalized patients with angina pectoris, 25 men and 15 women, 37 to 75 years of age, were subjected to Masters two-step test. Three hours before the test, 1.0 Gm. of pyridinolcarbamate or placebo was given orally using a double-blind technique. Before, immediately after, and 3, 5, 7, 10, and 30 minutes after exercise, electrocardiographic changes and clinical symptoms were observed. In 20 of the above subjects prothrombin activity, calcium clotting time, and the platelet and adhesive platelet count was measured. Thirty-three of the 40 patients pretreated with placebo developed ischemic ECG findings immediately to 10 minutes after the exercise test. Seventeen of the same 40 subjects pretreated with pyridinolcarbamate developed ischemic ECG findings. The difference between placebo and pyridinolcarbamate was statistically significant at p For the second exercise test the 17 patients who had received pyridinolcarbamate for the first test were pretreated with placebo, and 13 showed positive ischemic ECG changes. The 23 patients who had received placebo for the first exercise test were pretreated for the second test with pyridinolcarbamate, and 10 developed positive ECG changes. There was no significant difference noted between the two exercise tests in regard to the appearance of ischemic ECG changes. The appearance of anginal pain after exercise was prevented by pretreatment with pyridinolcarbamate (p In comparison to other 39 healthy volunteers, the patients with angina pectoris showed enhanced blood coagulability and lower platelet count. In healthy persons, enhanced blood coagulability was observed one minute after the exercise test (p p

EVALUATION OF EFFECT OF PYRIDINOLCARBAMATE ON CEREBROVASCULAR DISEASES UNDER CONTROLLED TRIAL

脳血栓38名および脳出血18名の発病30日以内の入院患者を対象とし, controlled trialの下, pyridinolcarbamateの臨床症状に対する改善効果並びに再発予防効果を検討した.患者を年令,性,疾患とその病日,症状およびその重症度,合併症,既往症がなるべく一致するよう27名と29名の2群にわけ,一群29名にpyridinolcarbamate 1日1.0～1.5g経口投与したほかは,両群とも全く同様の処置を行なつた,臨床症状を意識,言語,運動に5段階をもうけ記載し,観察開始時と,観察開始10日後のそれを比較することにより,臨床症状の推移をおつた.この結果,臨床症状改善率はpyridinolcarbamate投与群29例中25例, 86%にたいし,対照群27例中15例, 56%で両群間に推計学的に有意の差(P<0.05)を認めた.またpyridinolcarbamate群と対照群において,それぞれ最長63カ月および64カ月,平均31.4±5.9カ月, 31.6±4.8カ月にわたる観察期間での再発率は28例中4例, 14%にたいし23例中9例, 39%と推計学的有意差(P<0.05)を認めた.